TL;DR
Get workout gear delivered free — and shop member deals
- Fast, free delivery on millions of items
- Access to Prime Big Deal Days deals on October 6–7
- Prime Video, Amazon Music and more included
The FDA said Sept. 28, 2026, that it intends to evaluate changes to the regulatory framework for premarket tobacco product applications, including possible rulemaking to replace the current framework. The agency will continue reviewing applications and making decisions under statutory requirements while it considers its next steps.
The U.S. Food and Drug Administration said Sept. 28 that it intends to evaluate changes to the rules governing Premarket Tobacco Product Applications, including potentially starting rulemaking to replace the current framework. The agency said it will continue processing applications and issuing decisions under existing statutory requirements while that evaluation proceeds.
The FDA said its review will draw on its experience implementing the 2021 PMTA rule, recent judicial developments and changes in the tobacco-product market. The agency cited the development of what it described as a widespread illicit and unregulated market and the pace of new product introductions as factors informing its plans. These are the agency’s stated reasons for reassessing the framework, not findings that a replacement rule has already been drafted or adopted.
The announcement leaves the existing review process in place for now. The FDA said it will continue to process PMTA submissions, conduct premarket reviews and issue regulatory decisions on new tobacco products in accordance with requirements established by Congress. It also said it will continue applying the statutory standard for whether marketing a product is appropriate for the protection of public health, commonly referred to as APPH.
The agency said any future changes will be consistent with applicable law and include opportunities for public input. It did not announce a proposed rule, a timetable for rulemaking, or specific changes to application requirements. The immediate development is an intention to evaluate the framework, rather than a change to the rules now in force.
What a Framework Review Could Change
A possible rewrite could affect how tobacco-product manufacturers prepare applications, how the FDA reviews them and how predictable the process is for applicants and the public. The agency framed its objective as developing a modern framework that better reflects current market conditions and offers greater clarity and predictability, while retaining the statutory public-health standard.
For companies with pending or future applications, the distinction between review and rulemaking matters: the FDA says current submissions will keep moving under existing law, and has not announced that applications should be filed differently. For consumers and public-health groups, the review could shape how new tobacco products are assessed before marketing. Any effect on decisions or application timelines depends on changes the agency may propose and ultimately finalize.
The announcement also places the agency’s plans alongside a legal challenge to the current framework. But the FDA did not say the lawsuit has changed the rules, paused reviews or determined the outcome of its evaluation. The practical significance will depend on the content and timing of any formal proposal and the public process that follows.
As an affiliate, we earn on qualifying purchases.
The 2021 Rule and Current Reviews
The FDA’s announcement concerns the Premarket Tobacco Product Application system, through which the agency reviews new tobacco products before they can be marketed. The agency said its experience implementing the 2021 rule is one factor behind its reassessment. Its statement does not describe which parts of that rule it might revise or whether every part would be replaced.
The agency also referred to a federal lawsuit filed in the U.S. District Court for the Northern District of Texas that challenges the current regulatory framework. The FDA identified the case as a recent judicial development it is considering, but its release did not provide details about the claims, procedural status or any court ruling. The lawsuit is therefore relevant background, not evidence that the framework has already been invalidated.
Separately, the FDA pointed to the pace of new product introductions and illicit, unregulated products as market conditions informing its review. Those explanations reflect the agency’s account of why it wants to reassess the system. Its release provides no market counts, measurements or comparison period for those characterizations.
premarket tobacco application review kit
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Rulemaking Details Remain Open
The FDA has not specified what provisions it may change, whether it will formally begin rulemaking, or when a proposed rule could appear. It also has not said how a replacement framework, if pursued, would handle pending applications or alter review procedures. The announcement gives no deadline for the evaluation.
The status and potential effect of the federal lawsuit are also unclear from the release. The FDA did not report a decision in the case or say that the litigation requires an immediate change to its practices. Until the agency announces a formal action, the current statutory review process remains in effect, according to its statement.
public health tobacco testing devices
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Watch for a Formal Proposal
The next substantive step would be an FDA announcement setting out whether it will start a rulemaking and, if so, the scope and schedule. A proposed rule would give applicants, public-health organizations, consumers and other stakeholders details to assess and a channel to provide input. The agency has not announced when such a proposal might be issued.
In the meantime, the FDA says it will continue processing applications and issuing decisions under the existing statutory framework. Developments in the Texas lawsuit and any later agency notices may clarify how the reassessment proceeds, but the agency has not stated that either will pause current reviews.
tobacco product compliance testing
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Key Questions
What did the FDA announce?
The FDA said it intends to evaluate changes to the PMTA regulatory framework, potentially including rulemaking to replace the current framework. It has not announced a proposed or final replacement rule.
Will the FDA stop reviewing tobacco-product applications?
No. The agency said it will continue processing PMTA submissions, conducting premarket reviews and issuing decisions under statutory requirements established by Congress.
What reasons did the FDA give for the evaluation?
The FDA cited its experience implementing the 2021 rule, recent judicial developments, the development of an illicit and unregulated market, and the pace of new product introductions. The market descriptions are the agency’s statements; its release supplied no figures or measurement period.
Has the FDA said what the new rules would require?
No. The agency has not identified specific changes, issued a proposed rule or provided a timetable. It said future changes would follow applicable law and include opportunities for public input.
Source: primary
Halloween Picks
halloween
As an affiliate, we earn on qualifying purchases.
